Knight Therapeutics (OTCMKTS:KHTRF – Get Free Report) is expected to be posting its results before the market opens on Thursday, August 6th. Analysts expect Knight Therapeutics to announce earnings of $0.01 per share and revenue of $88.9650 million for the quarter.
Knight Therapeutics Trading Down 4.3%
Shares of OTCMKTS KHTRF opened at $6.72 on Wednesday. The firm’s 50-day moving average price is $6.71 and its 200-day moving average price is $5.60. Knight Therapeutics has a 1-year low of $4.07 and a 1-year high of $7.40.
Wall Street Analysts Forecast Growth
Separately, Royal Bank Of Canada reiterated an “outperform” rating on shares of Knight Therapeutics in a report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy”.
About Knight Therapeutics
Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.
Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.
Read More
- Five stocks we like better than Knight Therapeutics
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
